Junshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs

Bulletin Express

03/12

Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.

The company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.

Management confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.

The board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1179340994"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179340994\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179340994?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179340994","market":"us","top_or_hot":-1,"title":"Junshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs","media":"Bulletin Express","content":"<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.</p>\n<p>The company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.</p>\n<p>Management confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.</p>\n<p>The board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-12 19:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.</p>\n<p>The company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.</p>\n<p>Management confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.</p>\n<p>The board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君實生物","start_time":0,"source_url":"","article_id":"1179340994","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179340994","pubTimestamp":1773315771,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"君实生物(01877)全额返还此前用于营运资金需求的闲置募集资金11.1亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.\nThe company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.\nManagement confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.\nThe board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}